Atossa Therapeutics and Quantum Leap Healthcare Announce I-SPY 2 Clinical Trial To Evaluate (Z)-Endoxifen in Combination With Abemaciclib (VERZENIO^®) in Women With ER+/HER2- Breast Cancer

Atossa Therapeutics, Inc. and Quantum Leap Healthcare Collaborative™ announced the initiation of a new study to evaluate Atossa’s (Z)-endoxifen in combination with abemaciclib, a cyclin-dependent kinase inhibitor marketed by Eli Lilly and Company, in women with ER+/HER2- breast cancer.